NASDAQ:RSLS - Reshape Lifesciences Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $0.03 0.00 (0.00 %) (As of 10/23/2018 03:29 AM ET)Previous Close$0.0285Today's Range$0.03 - $0.0352-Week Range$0.03 - $31.80Volume1.58 million shsAverage Volume2.42 million shsMarket Capitalization$260,000.00P/E Ratio0.00Dividend YieldN/ABeta1.77 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email ReShape Lifesciences Inc., a medical device company, focuses on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases, and other gastrointestinal disorders. Its proprietary neuroblocking technology, vBloc Therapy is designed to intermittently block the vagus nerve using electrical impulses. The company's product portfolio includes ReShape vBloc, a therapy that enables patients to feel full and eat less by intermittently blocking hunger signals on the vagus nerve; and ReShape Balloon system that uses balloon technology designed to take up room in the stomach to enable people lose weight. Its product portfolio also comprises ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without permanently changing patient anatomy. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in October 2017. ReShape Lifesciences Inc. was founded in 2002 and is headquartered in San Clemente, California. Receive RSLS News and Ratings via Email Sign-up to receive the latest news and ratings for RSLS and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Electromedical equipment Sub-IndustryHealth Care Equipment SectorMedical SymbolNASDAQ:RSLS CUSIP29365M20 Webwww.enteromedics.com Phone949-429-6680 Debt Debt-to-Equity RatioN/A Current Ratio0.61 Quick Ratio0.37 Price-To-Earnings Trailing P/E Ratio0.00 Forward P/E Ratio-0.01 P/E GrowthN/A Sales & Book Value Annual Sales$1.29 million Price / Sales0.21 Cash FlowN/A Price / CashN/A Book Value$38.22 per share Price / Book0.00 Profitability EPS (Most Recent Fiscal Year)($47.68) Net Income$-33,810,000.00 Net Margins-2,397.35% Return on Equity-70.96% Return on Assets-60.41% Miscellaneous Employees83 Outstanding Shares9,010,000Market Cap$260,000.00 Reshape Lifesciences (NASDAQ:RSLS) Frequently Asked Questions What is Reshape Lifesciences' stock symbol? Reshape Lifesciences trades on the NASDAQ under the ticker symbol "RSLS." When did Reshape Lifesciences' stock split? How did Reshape Lifesciences' stock split work? Reshape Lifesciences shares reverse split on the morning of Monday, June 4th 2018. The 1-15 reverse split was announced on Friday, June 1st 2018. The number of shares owned by shareholders was adjusted after the closing bell on Friday, June 1st 2018. An investor that had 100 shares of Reshape Lifesciences stock prior to the reverse split would have 7 shares after the split. How were Reshape Lifesciences' earnings last quarter? Reshape Lifesciences Inc (NASDAQ:RSLS) issued its earnings results on Tuesday, August, 14th. The medical device company reported ($4.80) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($1.79) by $3.01. The medical device company had revenue of $0.65 million for the quarter. Reshape Lifesciences had a negative return on equity of 70.96% and a negative net margin of 2,397.35%. View Reshape Lifesciences' Earnings History. When is Reshape Lifesciences' next earnings date? Reshape Lifesciences is scheduled to release their next quarterly earnings announcement on Tuesday, November 13th 2018. View Earnings Estimates for Reshape Lifesciences. What is the consensus analysts' recommendation for Reshape Lifesciences? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Reshape Lifesciences in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Reshape Lifesciences. Are investors shorting Reshape Lifesciences? Reshape Lifesciences saw a decline in short interest in the month of September. As of September 28th, there was short interest totalling 1,159,023 shares, a decline of 49.3% from the September 14th total of 2,288,097 shares. Based on an average trading volume of 6,670,116 shares, the short-interest ratio is currently 0.2 days. Approximately 1.4% of the shares of the stock are sold short. View Reshape Lifesciences' Current Options Chain. Who are some of Reshape Lifesciences' key competitors? Some companies that are related to Reshape Lifesciences include Trimedyne (TMED), Magna-Lab (MAGAA), Guided Therapeutics (GTHP), 21st North (ULGX), IMRIS (IMRSQ), Echo Therapeutics (ECTE), Newcardio (NWCI), BioSig Technologies (BSGM) and SpectraScience (SCIE). Who are Reshape Lifesciences' key executives? Reshape Lifesciences' management team includes the folowing people: Mr. Dan W. Gladney, Chairman, Pres & CEO (Age 65)Mr. Scott P. Youngstrom, CFO, Sr. VP of Fin. & Sec. (Age 58)Mr. Naqeeb A. Ansari, VP of Worldwide Sales (Age 57)Dr. Mark B. Knudson Ph.D., Co-Founder and Special Advisor to the CEO (Age 69)Dr. Katherine S. Tweden Ph.D., Co-Founder (Age 57) How do I buy shares of Reshape Lifesciences? Shares of RSLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Reshape Lifesciences' stock price today? One share of RSLS stock can currently be purchased for approximately $0.03. How big of a company is Reshape Lifesciences? Reshape Lifesciences has a market capitalization of $260,000.00 and generates $1.29 million in revenue each year. The medical device company earns $-33,810,000.00 in net income (profit) each year or ($47.68) on an earnings per share basis. Reshape Lifesciences employs 83 workers across the globe. What is Reshape Lifesciences' official website? The official website for Reshape Lifesciences is http://www.enteromedics.com. How can I contact Reshape Lifesciences? Reshape Lifesciences' mailing address is 1001 Calle Amanecer, San Clemente CA, 92673. The medical device company can be reached via phone at 949-429-6680 or via email at [email protected] MarketBeat Community Rating for Reshape Lifesciences (NASDAQ RSLS)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 277 (Vote Outperform)Underperform Votes: 242 (Vote Underperform)Total Votes: 519MarketBeat's community ratings are surveys of what our community members think about Reshape Lifesciences and other stocks. Vote "Outperform" if you believe RSLS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RSLS will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 10/23/2018 by MarketBeat.com StaffFeatured Article: How is inflation measured?